MP-A08 is a first-in-class, highly selective, ATP competitive sphingosine kinase (SphK) inhibitor (Ki of 6.9/27 uM for SK2/SK1).

Moxonidine hydrochloride

Moxonidine

Mosedipimod (EC-18, 1-palmitoyl-2-linoleoyl-3-acetylglycerol) is a synthetic monoacetyldiaglyceride that stimulates T cell production of IL-2, IL-4, IL-12, IFN-γ, and GM-CSF in vitro.

Mosapride is a gastroprokinetic agent that acts as a selective 5HT4 agonist.

Monooctyl succinate is a monoester, which can be used as a surfactants and a potential fragrance releaser.

Monobenzone (Benoquin)

Mometasone furoate

Molsidomine is an orally active, long acting vasodilating drug, metabolized in the liver to the active metabolite linsidomine, which is an unstable compound that releases nitric oxide (NO) upon decay as the actual vasodilating compound.

Molindone is a therapeutic antipsychotic, used in the treatment of schizophrenia, works by blocking the effects of dopamine in the brain, leading to diminished psychoses.

MNK-IN-54 is a potent, orally bioavailable dual MNK1/2 and BCR-ABL1 inhibitor with IC50 of 20/10/200/10 nM for Abl T315I/ wt Abl/MNK1/MNK2, respectively.

MNKI-8e (MNK inhibitor 8e) is a potent, selective MNK inhibitor that inhibits Mnk2 with Ki of 0.37 uM, displays >34-fold and 4-fold over CDK2 (Ki>10 uM) and CDK9 (Ki=1.66 uM).

MNKI-85 is a potent and selective Mnk2 inhibitor with Ki of 31 nM, displays no inhibitory activities against Mnk1, CDK2A, CDK9T, and CDK4D.

MNKI-19 is a potent and dual-specific Mnk inhibitor with Ki of 186 nM and 68 nM for Mnk1 and Mnk2, respectively.

MNK inhibitor 9 is a potent, selective MAPK-interacting kinase (MNK1 and MNK2) inhibitor with IC50 of 3 nM for both, with no activity aginst CDK1/2 (IC50>25 uM).

MN30 (Methyl-3,4-dephostatin, APOBEC3G inhibitor MN30) is a first-in-class, selectve small molecule inhibitor of the single-strand DNA cytosine deaminase APOBEC3G with IC50 of 9.1 uM.

MN-001 (tipelukast), a novel, orally bioavailable drug, reduces fibrosis and inflammation and down-regulates TIMP-1, collagen Type 1 and LOXL2 mRNA overexpression

MMSET-IN-1 is a potent, selective epigenetic oncogene MMSET (aka NSD2 or WHSC1) inhibitor with Ki/IC50 of 1.6/3.3 uM.

MMRi64 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells.

MMRi6 is a small molecule inhibitor that disrupts Mdm2-MdmX RING-RING interaction interactions in vitro and activates p53 in cancer cells..

MMPI-1154 is a small molecule MMP-2 inhibitor with IC50 of 10/6.6/13/1.8 uM for MMP1/2/9/13, respectively.

MMP13-IN-31f is a highly potent, selective, orally bioavailable MMP-13 inhibitor with IC50 of 0.036 nM.

MMP13-IN-24f is a potent, selective, and orally active MMP-13 inhibitor with IC50/Ki of 0.5/0.19 nM, shows no activity against MMP-1 or TACE (IC50>10 uM).

MMK7 inhibitor 4a is a potent, sepecific, covalent inhibitor of MMK7, displays >800-fold selectivity over EGFR-WT and EGFR-L858R/T790M.

MMBO is a potent, highly selective, brain penetrant, orally active inhibitor of GSK-3 with IC50 of 37 and 53 nM for GSK-3α and GSK-3β, respectively.

MMAE-(PEG)4-DBCO is made by MMAE conjugated to DBCO-(PEG)4 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

MLS-1547 is a G protein-biased agonist of dopamine D2 receptors (EC50 = 0.37 μM in a calcium mobilization assay).

MLS1082 is a novel positive allosteric modulator of the D1 dopamine receptor, potentiatse dopamine-stimulated G-protein- and β-arrestin-mediated signaling and increase the affinity of dopamine for the D1 receptor with low micromolar potencies..

MLS-0437605 is a specific inhibitor of dual-specificity phosphatase 3 (DUSP3) with IC50 of 3.7 uM, 7-fold selectivity over USP22 and >4-fold selectivity over other 10 PTPs (HePTP, TCPTP, PTP1B, etc.).

MLS-0322825 is a novel potent low-molecular-weight protein tyrosine phosphatase (LMPTP) inhibitor with IC50 of 3.3 uM.